Lipid Pharmaceuticals Ehf.

Oculis Ehf

Oxymap Ehf.

Cyclops, Ehf.

Oxymap

Einar Stefansson

Thorsteinn Loftsson

Gisli Hreinn Halldorsson

Robert Arnar Karlsson

Sveinn Hakon Hardarson

Mar Masson

James M Beach

Jon Atli Benediktsson

Thor Eysteinsson

An anti-viral composition or formulation is described that includes free fatty acids ('FFA'). Also described, are methods of making and using such a composition or formulation.

Free fatty acids and methods of manufacture and use for treating coronavirus and other viral respiratory infections

A method and an apparatus for detecting change in retinal oxygen saturation over time are provided. The method includes the steps of capturing a first group of images of two or more wavelengths, calculating oxygen saturation of a vessel in the first group of images, storing the first group of images on a data storage device, capturing a second group of images of two or more wavelengths, calculating the oxygen saturation of a vessels in the second group of images, storing the second group of images on a data storage device, spatially registering the pair of the group of images, captured at different time and calculate the change in oxygen saturation. The method also includes means to validate whether an observed change in oxygen saturation is a real physiological change or artificial.

Temporal oximeter

The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g.), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

Fatty acids for use as a medicament

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.

Cyclodextrin nanotechnology for ophthalmic drug delivery

The example embodiments relate to a system for automatically evaluating oxygen saturation of the optic nerve and retina, including an image capturing system which includes a fundus camera, a four wavelengths beam splitter, a digital image capturing device, a computer system, and image processing software for registering and analyzing multi-spectral images of the retina, and for evaluating oxygen saturation level.

Automatic registration of images

Methods for enhancing the complexation efficiency of a drug with cyclodextrin and for enhancing the availability of a drug following administration of a cyclodextrin-drug complex.

Growing community of inventors

Reykjavik, Iceland

Einar Stefansson